companies karuna-therapeutics-inc 
Law 360 M&A
DECEMBER 22, 2023
Covington & Burling LLP-advised Bristol Myers Squibb said Friday it has agreed to buy Boston-based biotechnology company Karuna Therapeutics Inc. for $14 billion, leading Karuna's stock to jump more than 47% in pre-market trading.
Law 360 M&A
FEBRUARY 14, 2024
A Karuna Therapeutics Inc. shareholder has filed suit against the Boston-based biotechnology company alleging a proxy statement related to a proposed $14 billion buyout deal between Karuna and Bristol Myers Squibb contained false and misleading information and omitted key facts.
NYT M&A
DECEMBER 22, 2023
The deal is a bet on the growing market for psychiatric and neurological drugs.
Expert insights. Personalized for you.
52 
Let's personalize your content